| Change Password | Change User Info | CiteTrack Alerts | Access Rights | Subscription Help | Sign Out

# Published online August 14, 2003
PDF Version of this Article
Supporting Online Material
! Download to Citation Manager
Alert me when:
new articles cite this article
Search for similar articles in:
  Science Online
Search Medline for articles by:
Williams, B. G. || Dye, C.

Submitted on May 15, 2003
Accepted on August 5, 2003

Antiretroviral Drugs for Tuberculosis Control in the Era of HIV/AIDS

Brian G. Williams 1* Christopher Dye 1

1 Communicable Diseases, World Health Organization, 1211 Geneva 27, Switzerland.

* To whom correspondence should be addressed. E-mail: williamsbg@who.int.

HIV/AIDS has dramatically increased the incidence of tuberculosis (TB) in sub-Saharan Africa where up to 60% of TB patients are co-infected with HIV and each year 200,000 TB deaths are attributable to HIV co-infection. Now HIV threatens TB control in Asia, Eastern Europe and Latin America. Antiretroviral (ARV) drugs can prevent TB by preserving immunity but cohort analysis shows that early therapy, plus high levels of coverage and compliance, will be needed to avert a significant fraction of TB cases. However, ARVs could enhance the treatment of TB while TB programmes provide an important entry point for the treatment of HIV/AIDS.

Science 10.1126/science.1086845
Copyright © 2003 by The American Association for the Advancement of Science. All rights reserved.